Transjugular Liver Biopsy: The Adequacy and Safety.
- Author:
Do Ha KIM
1
;
Hong Ja KIM
;
Neung Hwa PARK
;
Geun Chan LEE
;
Young Wha CHUNG
;
Young Sang LEE
;
Dong Erk GOO
;
Hyeon Ki YOON
;
Kyu Bo SUNG
;
Eunsil YU
;
Dong Jin SUH
Author Information
1. Department of Internal Medicine, Diagnostic Radiology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Transjugular liver biopsy;
Complication
- MeSH:
Ascites;
Biopsy*;
Biopsy, Needle;
Diagnosis;
Fever;
Hematoma;
Humans;
Korea;
Liver Diseases;
Liver*;
Mortality;
Neck Pain;
Punctures;
Retrospective Studies
- From:Korean Journal of Medicine
1998;54(2):153-157
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Liver biopsy is an essential tool to confirm suspected diagnosis and to guide specific therapy in patients with liver disease. But, the standard percutaneous needle biopsy is contraindicated in patients with coagulopathy and large amount of ascites. The transjugular approach has been developed for these problem cases, but its efficacy and safety has not been adequately tested in korea. METHODS: We retrospectively analysed 21 transjugular liver biopsy cases, and the success rate of procedure, the adequacy of obtained specimen for diagnosis and procedure related complications were reviewed. RESULTS: The major reasons for trasjugular liver biopsy were coagulopathy(71%) and massive ascites(19%). Liver tissue was obtained successfully in 20 of 21 cases. The mean number of specimens was 3.4+/-1.1 per case and the mean size of specimen was 1.8+/-0.7mm. Pathologists reviewed and judged as adequate for diagnosis in 13 cases(65%), helpful in 6 cases(30%), and inadequate in 1 case. Minor complications such as neck pain, hematoma at puncture site, or transient fever occurred in 5 cases (23.8%) but there was no major complication or procedure-related mortality. CONCLUSION: Transjugular liver biopsy is a safe and valuable technique that provides adequate diagnostic informations in about two thirds of patients for whom conventional percutaneous biopsy is contraindicated.
